

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Dominique BOUREL et al.  
Title: USE OF ADCC-OPTIMIZED  
ANTIBODIES FOR TREATING  
WEAK PATIENTS  
Appl. No.: 10/566,358  
Filing Date: 04/13/2006  
Examiner: Ilia I. OUSPENSKI  
Art Unit: 1644  
Confirmation Number: 5572

OK to  
enter.  
/I.O./  
9/1/09

**SUPPLEMENTAL AMENDMENT AND REPLY UNDER 37 CFR 1.116**

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This communication is responsive to the final Office Action of March 31, 2009, and the Advisory Action of July 1, 2009. This communication conforms the Amendment filed June 24, 2009, to the comments in section 3(d) of the Advisory Action (objectionable antibody recitations are now omitted). Thus, this Supplemental Amendment places the application in condition for allowance. Accordingly, Applicants request entry.

A concurrently filed one-month extension of time makes this filing timely.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this document.

**Remarks/Arguments** begin on page 6 of this document.

Please amend the application as follows: